SignalFDA/Bio

CONNECT BIOPHARMA HOLDINGS LIMITED (CNTB) DISCUSSES TOPLINE RESULTS OF RADEMIKIBART PHASE 2 STUDY FOR ACUTE ASTHMA EXACERBATIONS TRANSCRIPT - SEEKINGALPHA

Topline Phase 2 results for rademikibart in acute asthma exacerbations drive biotech catalyst relevance.

What changed

Topline Phase 2 results for rademikibart in acute asthma exacerbations drive biotech catalyst relevance.

Why it matters

Topline Phase 2 results for rademikibart in acute asthma exacerbations drive biotech catalyst relevance. — impact context not separately stored; see What changed.

Sources

seekingalpha